This content is accessible only to 2020 ASCRS Virtual Annual Meeting attendees. If you attended the virtual meeting, please log in with the account associated with your virtual meeting registration. To log in, click the teal "Login" button in the upper right-hand corner of this page.
To evaluate the safety and efficacy of the OMNI Glaucoma Treatment System (Sight Sciences), a minimally invasive glaucoma surgery device combining viscodilation and trabeculotomy in eyes with open-angle glaucoma.
Retrospective chart review of 50 patients undergoing combined viscodilation and trabeculotomy for mild to moderate open-angle glaucoma were evaluated at a single center. Primary outcome measures included intraocular pressure (IOP) and number of glaucoma medications. Data was collected preoperatively and postoperatively at months 1 and 3. Safety was assessed by noting the need for secondary glaucoma procedures.
Mean pre-operative IOP was 15.6 mmHg on 1.3 IOP-lowering medications. At post-operative month 1, mean IOP decreased to 15.0 mmHg. By post-operative month 3, mean IOP decreased to 14.1 mmHg on 0.6 IOP-lowering medications. No secondary glaucoma procedures were required. Data will be updated prior to presentation at the ASCRS 2020 meeting.
The results of this study suggest the OMNI surgical system combining viscodilation and trabeculotomy is a safe and effective treatment option for eyes with open-angle glaucoma.
This presentation is from the session "SPS-105 Minimally Invasive Glaucoma Surgery: Viscocanalostomy, Combined Procedures, Outcomes" from the 2020 ASCRS Virtual Annual Meeting held on May 16-17, 2020.